Androgen-deprivation therapy in the management of neuroendocrine prostate cancer.

Background: Prostatic neuroendocrine carcinomas comprise <1% of all prostate neoplasms, and approximately 200 cases have been reported in the literature. We undertook this study to describe the experience in the management of prostatic neuroendocrine carcinoma with androgen-deprivation therapy (ADT).

Methods: We designed a retrospective, descriptive and observational study.

[Two methods for transrectal ultrasound-guided biopsy of the prostate: systematic vs. guided for suspect echogenic lesion].

Objective: We undertook this study to determine the efficiency of ultrasound-guided transrectal prostate biopsy applying two techniques: systematic extended vs. suspicious sonographic areas.

Methods: Medical files and histopathological reports were reviewed of patients who were treated at the Specialties Hospital of the 21st Century Medical National Center in Mexico City with suspicion of prostate cancer (T1, T2 and PSA <10 ng/ml).